New Clinical Trials of Griffithsin pharmaceutical designed against infection by coronaviruses

This is huge.  

Dr. Kenneth Palmer's group have been working hard to get a Griffithsin based pharmaceutical into clinical trials for some time and now a phase 1b trial is beginning. 

The pharmaceutical is designed to prevent entry into the cells by coronaviruses.

https://clinicaltrials.gov/ct2/show/NCT05437029

https://discoveria.com/studies/NCT05122260

The Pharmaceutical is in the form of a nasal spray which is an effective route to block the coronaviruses that gain access through the respiratory system.

Phase one trials are the first of four phases of clinical trials with human volunteers (They are now accepting volunteers for this study) designed to test the pharmaceutical on healthy individuals to see if any unwanted detrimental effects occur from the drug.  

If and when Q-Griffithsin is approved by the FDA, the method of biomanufacturing will likely involve large scale expression in plants, in this case nicotiana (tobacco).  

Congratulations, Dr. Palmer, on getting clinical trials underway!